(Reuters) - U.S. lab products provider Avantor Inc will buy Masterflex from privately held Antylia Scientific in a $2.9 billion all-cash deal to beef up its COVID-19 therapy and vaccine manufacturing ...
Antylia, a portfolio company of GTCR, has agreed to sell its Masterflex business unit to Avantor for $2.9 billion in all cash. The Masterflex arm is used by pharma and biotech customers for research ...
U.S. lab products provider Avantor Inc said on Tuesday it would buy Masterflex from privately held Antylia Scientific in a $2.9 billion all-cash deal that would strengthen its COVID-19 therapy and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback